flutiform 250 mikrogramm/10 mikrogramm/adag túlnyomásos inhalációs szuszpenzió
mundipharma ges.m.b.h - fluticasone propionate; formoterol fumarate -
flutiform k-haler 50 mikrogramm/5 mikrogramm/adag túlnyomásos inhalációs szuszpenzió
mundipharma ges.m.b.h - fluticasone propionate; formoterol fumarate -
flutiform k-haler 125 mikrogramm/5 mikrogramm/adag túlnyomásos inhalációs szuszpenzió
mundipharma ges.m.b.h - fluticasone propionate; formoterol fumarate -
tabinera 200 mg/245 mg filmtabletta
mensana pharma ltd. - emtricitabine; tenofovir disoproxil fumarate -
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, 2. típus - cukorbetegségben szedett gyógyszerek - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
dimetil-fumarát sandoz 120 mg gyomornedv-ellenálló kemény kapszula
sandoz hungária kft. - dimetil-fumarát -
dimetil-fumarát sandoz 240 mg gyomornedv-ellenálló kemény kapszula
sandoz hungária kft. - dimetil-fumarát -
dimetil-fumarát stada 120 mg gyomornedv-ellenálló kemény kapszula
stada arzneimittel ag - dimetil-fumarát -
dimetil-fumarát stada 240 mg gyomornedv-ellenálló kemény kapszula
stada arzneimittel ag - dimetil-fumarát -